Bailey D G, Dresser G K, Kreeft J H, Munoz C, Freeman D J, Bend J R
Department of Medicine, London Health Sciences Centre, University of Western Ontario, Canada.
Clin Pharmacol Ther. 2000 Nov;68(5):468-77. doi: 10.1067/mcp.2000.110774.
To determine whether unprocessed grapefruit can cause a drug interaction, whether the active ingredients are naturally occurring, and whether specific furanocoumarins or flavonoids are involved.
The oral pharmacokinetics of felodipine and its dehydrofelodipine metabolite were determined after administration of felodipine 10 mg extended-release tablet with 250 mL commercial grapefruit juice, homogenized grapefruit segments, or extract of segment-free parts equivalent to one unprocessed fruit or water in a randomized four-way crossover study. Inhibition of recombinant CYP3A4 by furanocoumarins (bergamottin, 6',7'-epoxybergamottin, 6',7'-dihydroxybergamottin) and flavonoids (naringenin optical isomers) was determined. Furanocoumarin and naringenin precursor (naringin) concentrations were measured in each grapefruit treatment.
Felodipine AUC with commercial grapefruit juice, grapefruit segments, or grapefruit extract was on average 3-fold higher than that with water. Felodipine peak concentration was higher, but the half-life was unchanged. The dehydrofelodipine/felodipine AUC ratio was reduced. The furanocoumarins produced mechanism-based and competitive inhibition of CYP3A4. Bergamottin was the most potent mechanism-based inhibitor. Naringenin isomers produced only competitive inhibition. Bergamottin, 6',7'-dihydroxybergamottin, and naringin concentrations varied among grapefruit treatments but were sufficient to inhibit markedly in vitro CYP3A4 activity.
Unprocessed grapefruit can cause a drug interaction with felodipine. The active ingredients are naturally occurring in the grapefruit. Bergamottin is likely important in drug interactions with commercial grapefruit juice. 6',7'-Dihydroxybergamottin and naringin may be more important in grapefruit segments because they are present in higher concentrations. Any therapeutic concern for a drug interaction with commercial grapefruit juice should now be extended to include whole fruit and possibly confectioneries made from grapefruit peel.
确定未加工的葡萄柚是否会引起药物相互作用,其活性成分是否天然存在,以及是否涉及特定的呋喃香豆素或黄酮类化合物。
在一项随机四交叉研究中,给予受试者10毫克非洛地平缓释片,同时分别服用250毫升市售葡萄柚汁、匀浆后的葡萄柚瓣、相当于一个未加工水果的无瓣部分提取物或水,然后测定非洛地平及其脱氢非洛地平代谢物的口服药代动力学。测定了呋喃香豆素(佛手柑内酯、6',7'-环氧佛手柑内酯、6',7'-二羟基佛手柑内酯)和黄酮类化合物(柚皮素光学异构体)对重组CYP3A4的抑制作用。测量了每种葡萄柚处理中呋喃香豆素和柚皮素前体(柚皮苷)的浓度。
与水相比,服用市售葡萄柚汁、葡萄柚瓣或葡萄柚提取物后,非洛地平的AUC平均高出3倍。非洛地平的峰值浓度更高,但半衰期不变。脱氢非洛地平/非洛地平的AUC比值降低。呋喃香豆素对CYP3A4产生基于机制的和竞争性抑制。佛手柑内酯是最有效的基于机制的抑制剂。柚皮素异构体仅产生竞争性抑制。佛手柑内酯、6',7'-二羟基佛手柑内酯和柚皮苷的浓度在不同的葡萄柚处理中有所不同,但足以显著抑制体外CYP3A4活性。
未加工的葡萄柚会与非洛地平发生药物相互作用。其活性成分天然存在于葡萄柚中。佛手柑内酯在与市售葡萄柚汁的药物相互作用中可能起重要作用。6',7'-二羟基佛手柑内酯和柚皮苷在葡萄柚瓣中可能更重要,因为它们的浓度更高。现在,任何对与市售葡萄柚汁药物相互作用的治疗关注都应扩展到包括整个水果以及可能由葡萄柚皮制成的糖果。